TLSA Stock Forecast & Price Target

Tiziana Life Sciences is attractive because its intranasal foralumab platform has shown repeated biomarker evidence of reduced CNS inflammation across SPMS, MSA, and Alzheimer’s disease, with upregulation of regulatory T-cells and TSPO-PET improvements that fit a coherent, disease-modifying mechanism. The company’s lead INFORM-MS Phase 2a study is a 48-patient, randomized, double-blind, placebo-controlled trial over 12 weeks, and the last patient completed the last visit on 9/21/26 with topline data expected in October, creating a near-term catalyst that could validate the broader pipeline. Confidence is further supported by 37 patient years of exposure with no serious adverse events and encouraging early clinical signals, including stability or improvement in the Expanded Access Program and up to 34% PET signal reductions in MSA, while the company’s SPMS, MSA, and AD readouts expected in the next 12 months could further de-risk the story.

Tiziana Life Sciences is a high-risk clinical-stage biotechnology company whose lead asset, Foralumab, has intriguing proof-of-biology in neuroinflammation but remains unproven as a durable disease-modifying therapy across na-SPMS, ALS, MSA, and Alzheimer’s. The bearish view is driven by major execution and financing risk: it has no approved products, has incurred significant operating losses since inception, and will need substantial additional capital, while the FDA may require two well-controlled trials and could limit reimbursement after accelerated approval. Competitive pressure is also intensifying from BTK and NLRP3 programs, and key intellectual-property control sits with licensors, adding third-party dependency risk.